Performance of the race-free CKD-EPI creatinine-based eGFR equation in a Danish cohort with measured GFR.

"CONFLICT OF INTEREST STATEMENT C.F.C., H.B., H.T.S., J.F., P.V.M., S.K.J., S.V.V. and U.H.-J. report employment with Aarhus University and Aarhus University Hospital. The Department of Clinical Epidemiology, Department of Biomedicine, Department of Renal Medicine, Department of Clinical Pharmacology and Department of Nuclear Medicine and PET-Centre at Aarhus University Hospital are involved in studies with funding from various companies as research grants to (and administered by) Aarhus University. None of these is related to this study. H.B. also reports consultancy agreements with AstraZeneca, Galapagos and Vifor Pharma, as well as research funding from GlaxoSmithKline (GSK) and Vifor Pharma, and reports honoraria from Alexion, AstraZeneca, MSD, Novartis Healthcare, NOVO Nordisk and Otsuka Pharmaceuticals. None of these is related to this study."

"FUNDING This study was supported by the Independent Research Fund Denmark (grant number 0134-00407B)."

"We included the following covariates: age and sex obtained from the Civil Registration System; morbidities obtained from the patient registry, including diabetes, heart failure, liver disease and lung disease; the presumed indication for mGFR, including candidacy for a kidney, liver, lung or heart transplant, congenital malformation of the urinary system, benign tumor in the urinary system, palsy, and psoriasis or atopic dermatitis possibly related to administration of calcineurin inhibitors; and CKD identified from the laboratory databases, defined as two outpatient eGFR values <60 mL/min/1.73 m2, according to either CKD-EPI21 or CKD-EPI09-NB, ≥90 days apart (see the Codebook in the for codes, definitions, and look-back and look-forward periods)."